You are here:

fondiparinux sodium (Arixtra)

Advice

Following a full submission

fondaparinux sodium (Arixtra®) is accepted for use within NHS Scotland for the treatment of ST segment elevation myocardial infarction (STEMI) in patients who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy.

Fondaparinux significantly reduced mortality and reinfarction during the 30 days following onset of symptoms compared to placebo and was not associated with an increased risk of bleeding.

Drug Details

Drug Name: fondiparinux sodium (Arixtra)
SMC Drug ID: 439/08
Manufacturer: GlaxoSmithKline UK Ltd
Indication: Treatment of ST segment elevation myocardial infarction (STEMI) in patients who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy.
BNF Category:
Sub Category: 2.8 Anticoagulants and protamine
Submission Type: Full submission
Status: Accepted
Date Advice Published: 11 February 2008

Back